which is a long-known mechanism of stress tolerance in mammalian cells, 17 may play a role in BRAFi-resistance as well. [18] [19] [20] [21] The effect on AKT activity may also explain the protective effect of certain receptor tyrosine kinases. [22] [23] [24] Importantly, chemical inhibitors of this pathway sensitize BRAFmutant cells to BRAFi, [25] [26] [27] [28] hinting at the possibility to increase the efficacy of therapy by using appropriate drug combinations.
Conceivable, an additional event that is functionally equivalent to BRAF activation would protect BRAF-mutant cells from BRAFi.
In accordance with the theory that MAP kinase cascade activation is the key oncogenic function of BRAF, multiple alternative means of maintaining high ERK activity have been shown to circumvent BRAF inhibition in vitro and in vivo. 23, [29] [30] [31] Generally, an evidence of functional equivalence could be mutual exclusivity with BRAF mutations despite frequent occurrence in the same cancer type.
Activation of proto-oncogene NRAS, which is found in many melanomas, fits this profile well. Activated NRAS negates the effects of BRAFi when introduced into BRAF-mutant cells, and is found in BRAFi-resistant cases of BRAF-mutant malignancies. 32 Another event, which is seen in some melanomas with wild type BRAF and NRAS, is activation of a small GTPase, RAC1. 5 Although the original research on RAC1 functions was focused on its role in cytoskeleton organization and cell motility, there are evidences connecting RAC1 signaling to the MAP kinase cascade. Accordingly, it was reported that activated forms of RAC1 can protect BRAF-mutated cells from BRAFi. 33 Perhaps the best-known downstream effector of RAC1 is p21-activate kinase 1 (PAK1), a serine-threonine kinase, which is involved in a plethora of physiological and pathophysiological processes. 34 Among the reported functions of PAK1 is co-activation of the MAP kinase cascade through interactions with RAF proteins 35, 36 and MEK1. 37 PAK1
was also reported to interact directly with AKT, 38 and is a critical cofactor in AKT-mediated oncogenic transformation. 39 Importantly, unlike RAS and RAC GTPases, PAK kinases are readily amenable to chemical inhibition, with multiple agents with various degrees of specificity currently used in pre-clinical and early-stage clinical studies. 40 We set forth to investigate the role of PAK1 in resistance and sensitivity to BRAFi in BRAF-mutated cells. We observed that hyperactive PAK1 provides substantial protection, while genetic and pharmacological inhibition of that protein had a sensitizing effect and reduced protection by active forms of RAC1 and AKT. These findings yield insights into the avenues to augment the efficacy and extend the utility of an important class of anti-cancer agents.
| MATERIALS AND METHODS

| Cell culture and reagents
All cell lines were cultured in humidified incubators at 37°C in the presence of 5% CO 2 . A375 (obtained from ATCC), HT29 (a gift from Dr. Yuri Ionov) and Colo205 (obtained from ATCC) were maintained in high-glucose Dulbecco's Modified Eagle Medium (DMEM).
SK-MEL-28 (obtained from ATCC) were maintained in Minimum Essential Media (MEM). B-CPAP (a gift from Dr. Katerina Gurova) were maintained in RPMI1640. All culture media were supplemented with penicillin (100 U/ml), streptomycin (100 µg/mL) and fetal bovine serum (10%). 
| Vectors and viral transduction
Lentiviral vector pLM-CMV-neo and its derivative pLM-CMV-mAKTneo (expressing a myristoylated form of mouse Akt1) were gifts of Dr.
Peter Chumakov. pBabe-PAK1-T423E was constructed by introducing PAK1 T423 coding fragment from pCMV6M-PAK1-T423E (a gift of Dr. Jonathan Chernoff, procured as Addgene plasmid #12208) into pBabeHygro. 42 pLX304 was a gift from Dr. David Root (procured as Addgene plasmid #25890). pLX304-RAC1-P29S was generated by PCR-based mutagenesis from pLX304-RAC1 (purchased from DNASU Plasmid Repository). The NRAS expression construct was a gift from Dr. Mikhail Nikiforov. RNA interference reagents were purchased from the Roswell Park Cancer Institute shRNA Core.
Lentiviral transduction was performed as described elsewhere. 43 Gamma-retroviral vectors were used as before. Membranes were probed overnight in 5% BSA at 4°C with gentle rocking with antibodies at manufacturers' recommended dilutions.
| Tissue microarray
An arrayed collection of metastatic melanoma samples 45 48 In agreement with earlier reports, 33 ectopic expression of a cancer-derived RAC1 mutant (RAC1 P29S) increased resistance of these cells to PLX4720 and vemurafenib ( Fig. 1A and S1A ). Resistance was associated with retention of higher activity of the MAP kinase cascade, as is indicated by higher levels of active (phosphorylated) forms of ERK1 and ERK2 ( Fig. 1C and E).
There are ample evidences demonstrating that multiple biological functions of RAC1 are mediated through activation of PAK kinases, and PAK1 in particular. 34 In order to explore whether BRAFiresistance follows the same pattern, we reduced the levels of PAK1 using RNA interference. The results demonstrated that expression of anti-PAK1 shRNA caused considerable re-sensitization of the RAC1P29S-expressing cells ( Fig. 1A and B), which was paralleled by lower ERK phosphorylation in drug-treated cells (Fig. 1C ).
Incomplete re-sensitization might have been caused by incomplete knockdown of PAK1, or by partial compensation of PAK1 functions by other kinases of the PAK family.
Importantly, a sensitizing effect of the shRNA was also seen in the absence of constitutively active RAC1 (Fig. 1A ). This is not surprising, as the control cells have some endogenous PAK1 activity, which may be contributing to their drug tolerance.
SK-MEL-28 is another metastatic melanoma cell line with an activating mutation in BRAF. In our experiments, SK-MEL-28 cells were somewhat more resistant to BRAFi than A375, but they too were sensitized by interference with PAK1 (Fig. S4 ).
The data on genetic interference was corroborated by the results of chemical inhibition of PAK1. Two compounds were used: IPA3 prevents activation of group I PAKs by upstream G-proteins, 49 while PF3758309
is a pan-PAK inhibitor, which competes with ATP binding. 40 Interestingly, both of these agents, when administered individually, were somewhat more toxic to cells with constitutively active RAC1 (Fig. 1D , (Fig. 1D) . Furthermore, the doses of vemurafenib and PF3758309, which alone were insufficient to affect ERK activity in cells with activated RAC1, achieved a pronounced affect when combined together (Fig. 1E ).
Akin to the data on the effects of anti-PAK1 shRNA, addition of PF3758309, or IPA3 to vemurafenib also increased the efficacy against A375 cells, as was evident both by cell survival and ERK phosphorylation data ( Fig. 1D and E). Overall, we concluded that inhibition of PAK, and PAK1 in particular, sensitizes BRAF-mutant melanoma cells to BRAFi, and negated the protective benefit of RAC1 activation.
Interestingly, we consistently observed a decrease in the abundance of the active form of PAK1 in BRAFi-treated cells. This is consistent with the recently proposed BRAF-dependent, RAC1-independent mechanism of PAK1 activation. 50 The effect was diminished by concomitant expression of activated RAC1
( Fig. 1C and E) , which also supports the hypothesis about BRAF and RAC1 affecting PAK1 status via parallel mechanisms. Considering the widespread involvement of PAK1 in cell growth, survival, and metabolism, 34 its eventual inhibition by BRAFi may be an important contributor to the anti-tumor effects of this class of compounds, while RAC1-independent control of PAK1 by BRAF may explain some features of BRAF-mutant cells.
| Activation of PAK1 conveys resistance to BRAF inhibitors
If PAK1 is an important downstream effector of RAC1 in the BRAFiresistance phenomenon, then one may expect that PAK1 activation alone is able to recapitulate the protective effect. Indeed, we observed that ectopic expression of constitutively active PAK1 increased tolerance of A375 cells to PLX4720, resulting in higher IC 50 values ( Fig. 2A and B ) and higher levels of active (phosphorylated) components of MAP kinase cascade (Fig. 2C) . Accordingly, activated PAK1 allowed the cells to maintain a higher proliferative potential in the presence of modest doses of PLX4720, as attested by a higher proportion of cells undergoing DNA replication under these conditions ( Fig. 2D and E) . Importantly, BRAF-mutant colon carcinoma line Colo205, which is among the most sensitive colon cancer lines to RAF inhibition, 51 was also protected by constitutively active PAK1 ( Fig. S5A and B). This indicates that the phenomenon is not limited to cells of melanoma origin.
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Of note, activated PAK1 also increased resistance of A375 to a MEK inhibitor AZD6244 52 ( Fig. S6) . Thus, our observations argue that activation of PAK1 may serve as a protective mechanism against the anti-tumor activity of BRAFi, and possibly, other anti-cancer agents that target the MAP kinase cascade.
| Inhibition of PAK1 negates AKT-mediated resistance to BRAF inhibitors
Activation of the PI3K-AKT signaling pathway is a common occurrence in cancers, where it contributes to a plethora of biological and biochemical features of malignant cells. 17 As mentioned above, it is one of the better-known modes of resistance to BRAFi. It was reported that AKT directly interacts with PAK1, 53 and PAK1 function is important for the maintenance of transformed phenotypes in AKT-transformed cells. 39 We set forth to explore whether AKTmediated protection is affected by PAK1 status.
As expected, a constitutively active form of AKT (myristoylated, aka mAKT) increased resistance of A375 cells to PLX4720 | 1519 (Fig. 3A and B) . However, an shRNA against PAK1 was able to reduce the resistance of mAKT-bearing cells to the level of the parental cell line (Fig. 3B) . Furthermore, cells harboring activated AKT were more sensitive to PF3758309, a pan-PAK chemical inhibitor (Fig. 3C, Fig. S2B ). Importantly, a combination of BRAF and PAK inhibitors (PLX4720 and PF3758309) was effective against mAKT-expressing and parental A375 cells (Fig. 3C ). This observation suggests PAK inhibition as a strategy to negate the protective effects of AKT activation in BRAFi-treated cancers.
| PAK inhibitor synergizes with BRAFi in intrinsically BRAFi-resistant cell lines
It is well known that some cancer cases, as well as some cancer- is approximately 300-fold higher than that of A375 (Fig. 4A, compare to Fig. 1A) . In these cells, PAK inhibitor PF3758309 greatly synergizes with PLX4720 at a range of doses ( Fig. 4B and C).
Similarly, a BRAF-mutant colorectal carcinoma cell line HT29
has demonstrated exceptional resistance to RAF inhibitor GDC-0879. 51 It was also insensitive to vemurafenib in our experimental (Fig. 4D) , but was synergistically suppressed by a vemurafenib/PF3758309 combination using the doses of the compounds that were ineffectual when applied individually ( Fig. 4E and F ).
Our observations suggest that, at least in some cases, a combination of PAK and BRAF inhibitors may improve the initial response to BRAFi therapy and might extend the utility of this therapy to a broader range of malignancies. In our experiments we relied on two BRAF inhibitors: vemurafenib and PLX4720. Although the compounds share considerable structural similarity and are expected to affect mutant BRAF in a similar manner, they are sufficiently distinct to differ in their interactions with some other biological molecules. 54 The fact that in our system qualitatively consistent results were obtained using both inhibitors (Fig. S7 and data not shown) reduces the possibility that the observed phenomena are caused by off-target effects of these compounds.
Interestingly, PAK1 follows the mutual exclusivity pattern seen among other frequently mutated oncogenes: BRAF, NRAS, and RAC1. While the latter oncogenes in melanomas are commonly afflicted by point mutations, PAK1 gene is amplified in 5% cases (Fig. S8 ). PAK1 amplification is mutually exclusive with BRAF mutations (P = 0.01), which is consistent with the hypothesis that the two events make equivalent contributions to oncogenesis. As discussed earlier, 34 PAK1 is amplified as a part of a larger amplicon, which, typically, includes, among other genes, cyclin D1. PAK1 is also an essential oncogenic regulator of cyclin D1, 55 and, conceivably, co-amplification of the two provides a potent stimulus for tumor progression.
PAK kinases, and PAK1 in particular, have received considerable attention as therapeutic targets for various health conditions. 34 58 This phenomenon was later confirmed by others, 59 but the reason for differential sensitivity is still unclear. It is possible that RAS-mutant cells are "addicted" to PAK function because the latter is needed to alleviate some of the stress associated with RAS hyperactivity. Alternatively, the difference may be in the reliance of RAS cells on wild type CRAF, whose full activation is PAK1-dependent, 60 while activated BRAF V600E mutant is fully functional without phosphorylation on the site targeted by PAKs. 36 Of note, increased reliance on CRAF has been previously reported in some BRAFi-resistant cells. 25 Importantly, the functions of PAK1 extend well beyond the regulation of MAP kinase cascade. 34 One might speculate that in RAS-mutant cells these functions are maintained via RASdependent activation of PAK1, while in BRAF cells this is fulfilled by alternative, PAK1-independent, mechanisms. However, a recent report suggests that BRAF has an activating effect on PAK1, and that small GTPases, traditional PAK1 activators, play no role in this phenomenon. 50 In this case, it is conceivable that the relative resistance of BRAF-mutant cells to PAK1 inhibition is simply the result of a more robust activation of PAK1. Of note, in our earlier study, 58 we used IPA3, a PAK1 inhibitor, which acts through preventing PAK1 activation by upstream small GTPases 49 and
would not be expected to affect the BRAF-mediated mechanism of activation. Interestingly, a small GTPase-independent mode of PAK activation has been previously proposed for AKT. 38 The data presented here is consistent with the existence of parallel BRAF-dependent and RAC1-dependent modes of PAK1 activation. Indeed, inhibition of BRAF in BRAF-mutant cells resulted in pronounced decrease in PAK1 activity, but this effect was abrogated by expression of a constitutively active RAC1 (Fig. 1C and E) . It is tempting to speculate that eventual reduction of PAK1 activity contributes to the efficacy of BRAF inhibitors, while an ability to maintain PAK1 would decrease the therapeutic response. Furthermore, since PAK1 activation alone is sufficient to protect cells from BRAFi, one may predict that many more direct or indirect PAK1
activators could enhance cell resistance to these drugs. In this regard, it is worth mentioning that ARGEF2 (Rho/Rac Guanine Nucleotide Exchange Factor 2) was found in an insertional-mutagenesis based screen for vemurafenib resistance genes. 20 ARHGEF2 is an activator of RAC1. 61 It also interacts directly with PAK1, 62 although the biological significance of this interaction is still unclear. ARHGEF7 (aka β-PIX), another member of ARHGEF family and a classic RAC1
activator, 63 exhibits a point mutation and a copy number gain in HT29 cells (data accessed via www.cbioportal.org). Bearing in mind that this cell line is relatively resistant to BRAFi and is sensitized by PAK inhibitors ( Fig. 4D and E) , it would be interesting to explore the role of ARHGEF7 changes in these phenomena. Also noteworthy is that the identity of the activating GEF determines the pattern of proteinprotein interactions and, hence, the exact consequences of RAC1 activation. 64 Therefore, it is worthwhile exploring whether only a subset of GEFs can confer RAC1-mediated protection from vemurafenib.
In our collection of melanoma tissues samples ( PF3758309 is considered a pan-PAK inhibitor. 40 Our genetic experiments with ectopic expression of activated PAK1 and with PAK1-specific RNA interference prove that PAK1 specifically can provide drug resistance and can be targeted for sensitization, at least in our model systems. However, evolutionary conservation in the PAK family makes it likely that the members share at least some of the targets, and a RAC1-dependent pro-proliferative function has been reported for PAK2. 65 Thus, it is conceivable that activation of more than one distinct PAK isoform could lead to the drug-resistant phenotype. Indeed, involvement of other PAKs could be one of the explanations for why the sensitizing effect of chemical inhibitors noticeably exceeds that of PAK1 shRNA in RAC1-transduced cells.
Furthermore, PAK3, which is functionally and structurally close to PAK1, was borderline-effective in a genetic screen of a collection of kinases for the ability to enhance vemurafenib resistance. 29 In the latter case, a wild-type PAK3 variant was expressed, leaving open a possibility that a stronger effect could have been achieved by an activated from or in the presence of an additional activating signal.
The similarities and differences among the PAK proteins in regard to their roles in BRAFi response merits further investigation. However, it is important to note that all of the anti-PAK compounds currently reported in pre-clinical or early-clinical pipelines are active against, at least, all group I PAKs. 40 Thus, any functional redundancy among
PAKs in cancer cells is unlikely to reduce the clinical prospects of these compounds.
The possibility that resistance to BRAFi may be coupled to a therapeutically exploitable vulnerability has been discussed in literature. 66, 67 It is intriguing that activation of RAC1 or AKT in BRAF-mutant cells not only increases the resistance of these cells to BRAFi, but also sensitizes them to PAK inhibitors. While the molecular underpinning of this sensitivity is yet to be discovered, 
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